JP5070052B2 - Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法 - Google Patents

Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法 Download PDF

Info

Publication number
JP5070052B2
JP5070052B2 JP2007527993A JP2007527993A JP5070052B2 JP 5070052 B2 JP5070052 B2 JP 5070052B2 JP 2007527993 A JP2007527993 A JP 2007527993A JP 2007527993 A JP2007527993 A JP 2007527993A JP 5070052 B2 JP5070052 B2 JP 5070052B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sildenafil
cardiac
composition according
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007527993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510705A5 (https=
JP2008510705A (ja
Inventor
カシュ デービッド
英樹 瀧本
シャンピオン ハンター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2008510705A publication Critical patent/JP2008510705A/ja
Publication of JP2008510705A5 publication Critical patent/JP2008510705A5/ja
Application granted granted Critical
Publication of JP5070052B2 publication Critical patent/JP5070052B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007527993A 2004-08-17 2005-08-17 Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法 Expired - Fee Related JP5070052B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60213404P 2004-08-17 2004-08-17
US60/602,134 2004-08-17
PCT/US2005/029327 WO2006023603A2 (en) 2004-08-17 2005-08-17 Pde5 inhibitor compositions and methods for treating cardiac indications

Publications (3)

Publication Number Publication Date
JP2008510705A JP2008510705A (ja) 2008-04-10
JP2008510705A5 JP2008510705A5 (https=) 2008-10-23
JP5070052B2 true JP5070052B2 (ja) 2012-11-07

Family

ID=35968156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007527993A Expired - Fee Related JP5070052B2 (ja) 2004-08-17 2005-08-17 Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法

Country Status (7)

Country Link
US (1) US8299083B2 (https=)
EP (1) EP1786428B1 (https=)
JP (1) JP5070052B2 (https=)
CN (1) CN101106997A (https=)
AU (1) AU2005277384B2 (https=)
CA (1) CA2577442A1 (https=)
WO (1) WO2006023603A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841300B2 (en) * 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
CA2687679A1 (en) * 2007-05-18 2008-11-27 Vivus, Inc. Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment
JP5730575B2 (ja) 2007-10-01 2015-06-10 リクスト・バイオテクノロジー，インコーポレイテッド Ｈｄａｃ阻害剤
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
TW201249843A (en) * 2011-06-14 2012-12-16 Univ Kaohsiung Medical Processes for preparing amine salts of KMUP-3 and use thereof
US8623924B2 (en) 2011-07-15 2014-01-07 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
MX2015006023A (es) * 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
WO2014081958A1 (en) 2012-11-21 2014-05-30 Cardiomems, Inc. Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
US9198908B2 (en) * 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
EP3110507B1 (en) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
KR20190049691A (ko) * 2016-07-07 2019-05-09 카듀리온 파마슈티칼스, 엘엘씨 심부전의 치료 방법
EP4324477A3 (en) 2016-12-08 2024-05-22 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
JPWO2018124236A1 (ja) * 2016-12-27 2019-11-14 国立大学法人大阪大学 難治性心疾患治療用医薬組成物
US20210386743A1 (en) * 2018-10-08 2021-12-16 The Johns Hopkins University Use of pde9 inhibitors for treatment
WO2025226615A1 (en) * 2024-04-22 2025-10-30 Huyabio International, Llc Sodium salt and ethanolamine salt of 23-hydroxytormentic acid

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5155120A (en) * 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
WO1998019594A1 (en) 1996-11-04 1998-05-14 The Johns-Hopkins University Assessing cardiac contractility and cardiovascular interaction
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
EP0977756A1 (en) 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
PL339836A1 (en) 1998-02-19 2001-01-02 Eisai Co Ltd Phtalazine compounds and therapeutic agents suitable to treat erection disorders
HRP20000712A2 (en) * 1998-04-20 2001-06-30 Pfizer PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CZ20012627A3 (cs) * 1999-01-20 2002-01-16 Arzneimittelwerk Dresden Gmbh Pouľití imidazo [1,5-a] pyrido [3,2-e]pyrazinonů jako léčiva
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
CA2406947A1 (en) 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
CA2411008C (en) 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
EP1366049B1 (en) 2000-06-23 2006-06-21 Lilly Icos LLC Pirazino¬1'2':1,6|pyrido¬3,4-b|indole derivatives
ES2269408T3 (es) 2000-06-23 2007-04-01 Lilly Icos Llc Inhibidores de fosfodiesterasa especifica de gmp ciclico.
EP1313736B1 (en) 2000-06-26 2005-07-27 Lilly Icos LLC Condensed pyrazindione derivatives as inhibitors of pde5
EP1335923B1 (en) 2000-10-03 2006-07-12 Lilly Icos LLC Condensed pyridoindole derivatives
ATE337320T1 (de) 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
GB0202254D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US7091207B2 (en) 2002-05-22 2006-08-15 Virginia Commonwealth University Method of treating myocardial infarction with PDE-5 inhibitors
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
WO2004037183A2 (en) 2002-10-22 2004-05-06 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases
CA2533715A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction

Also Published As

Publication number Publication date
CN101106997A (zh) 2008-01-16
JP2008510705A (ja) 2008-04-10
AU2005277384A1 (en) 2006-03-02
AU2005277384B2 (en) 2011-11-17
EP1786428A4 (en) 2009-08-05
EP1786428A2 (en) 2007-05-23
CA2577442A1 (en) 2006-03-02
WO2006023603A2 (en) 2006-03-02
US8299083B2 (en) 2012-10-30
WO2006023603A3 (en) 2006-10-19
US20090062313A1 (en) 2009-03-05
EP1786428B1 (en) 2012-05-16

Similar Documents

Publication Publication Date Title
JP5070052B2 (ja) Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
Takimoto et al. Oxidant stress from nitric oxide synthase–3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load
Bracey et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin‐1β
Li et al. Activation of NADPH oxidase mediates increased endoplasmic reticulum stress and left ventricular remodeling after myocardial infarction in rabbits
Tsai et al. Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes
Mátyás et al. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
Kishore et al. Interleukin-10 inhibits chronic angiotensin II-induced pathological autophagy
US20180193458A1 (en) Compositions and methods for treating senescence-associated diseases and disorders
Mima et al. Implications of treatment that target protective mechanisms against diabetic nephropathy
Hirata et al. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK‐ERK pathway coupling with Pyk2
JP2014533697A (ja) デフェリプロンを用いた処置方法
Shah et al. Angiotensin-(1–7) stimulates high atrial pacing-induced ANP secretion via Mas/PI3-kinase/Akt axis and Na+/H+ exchanger
Lee et al. Differential effects of NADPH oxidase and xanthine oxidase inhibition on sympathetic reinnervation in postinfarct rat hearts
US20040214836A1 (en) Method of treatment of myocardial infarction
US12465605B2 (en) Methods and materials for gender-dependent treatment of cardiovascular dysfunction
US20100004248A1 (en) Use of a Nitric Oxide Synthase Modulator for the Treatment of Cardiac Indications
KR101093930B1 (ko) 스코파론의 신규 용도
PL209912B1 (pl) Zastosowanie inhibitora kinazy tyrozynowej w medycynie
Blondin et al. Human BAT thermogenesis is stimulated by the β 2-adrenergic receptor
CA2504388A1 (en) Quinazolinone compositions for regulation of gene expression related to pathological processes
Hirose et al. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects
WO2025096597A1 (en) Compositions including inhibitors of pten expression or activity to prevent or treat type 2 diabetes
Marín-García Signaling Cascades in Heart Failure: From Cardiomyocytes Growth and Survival to Mitochondrial Signaling Pathways
Nakagami et al. Aging of Blood Vessels
Farahmand Beneficial effects of probucol in experimental model of cor pulmonale

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120724

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120820

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150824

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees